Difference between revisions of "Talimogene laherparepvec (Imlygic)"
Jump to navigation
Jump to search
| Line 20: | Line 20: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | Andtbacka, H et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015:2812-2814. | + | *Andtbacka, H et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015:2812-2814. |
| − | + | *Lawler SE, Chiocca EA. Oncolytic Virus-Mediated Immunotherapy: A Combinatorial Approach for Cancer Treatment. J Clin Oncol. 2015;33(25):2812-4. | |
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Oncolytic viral therapy]] | [[Category:Oncolytic viral therapy]] | ||
[[Category:Drugs FDA approved in 2015]] | [[Category:Drugs FDA approved in 2015]] | ||
Revision as of 05:41, 28 October 2015
General information
Class/mechanism: Oncolytic Viral Therapy
Route: SC (injectable)
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, , UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Patient counseling information can be found on Amgen Patient Medication Guide[1]
Also Known As
- OncoVEXGM-CSF
- T-VEC
- Imlygic
Prescribing information
Prescribing information for healthcare providers
References
- Andtbacka, H et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015:2812-2814.
- Lawler SE, Chiocca EA. Oncolytic Virus-Mediated Immunotherapy: A Combinatorial Approach for Cancer Treatment. J Clin Oncol. 2015;33(25):2812-4.